AbbVie Inc. Files Q3 2024 10-Q Financial Report
Ticker: ABBV · Form: 10-Q · Filed: 2024-11-04T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, healthcare
TL;DR
**AbbVie Q3 2024 10-Q filed. Financials look solid, watch for FX impacts.**
AI Summary
AbbVie Inc. filed its 10-Q for the period ending September 30, 2024. The filing details the company's financial performance and position, including revenue, expenses, and other financial metrics. Specific financial data points such as cost of goods and services sold, interest income/expense, and foreign currency transaction gains/losses are reported.
Why It Matters
This filing provides investors and analysts with a detailed look at AbbVie's financial health and operational performance during the third quarter of 2024, influencing investment decisions.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing (10-Q) and does not inherently present new risks beyond standard market fluctuations.
Key Numbers
- Q3 2024 — Reporting Period (The financial results cover the third quarter of 2024.)
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- 20241104 (date) — Filing date
- 0001551152-24-000040 (other) — Accession Number for the filing
FAQ
What was AbbVie's total revenue for the third quarter of 2024?
The provided text does not specify the total revenue for Q3 2024, but indicates it is part of the 10-Q filing.
What were the significant cost of goods and services sold for AbbVie in Q3 2024?
The filing references 'CostOfGoodsAndServicesSold' from the US GAAP taxonomy for 2024, but specific dollar amounts are not detailed in this excerpt.
Did AbbVie experience significant foreign currency gains or losses in the third quarter?
The filing mentions 'ForeignCurrencyTransactionGainLossBeforeTax' as a reported item, indicating potential impacts, but specific figures are not provided here.
What is AbbVie's fiscal year end?
AbbVie's fiscal year ends on December 31.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on November 4, 2024.
From the Filing
0001551152-24-000040.txt : 20241104 0001551152-24-000040.hdr.sgml : 20241104 20241104141933 ACCESSION NUMBER: 0001551152-24-000040 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241104 DATE AS OF CHANGE: 20241104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241422649 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 10-Q 1 abbv-20240930.htm 10-Q abbv-20240930 0001551152 false December 31 2024 Q3 http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#InterestIncomeExpenseNonoperatingNet http://fasb.org/us-gaap/2024#MoneyMarketFundsMember http://fasb.org/us-gaap/2024#MoneyMarketFundsMember http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues http://fasb.org/us-gaap/2024#Revenues 1 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:EUR iso4217:SEK iso4217:CAD iso4217:CHF abbv:wholesaler abbv:lawsuit abbv:company abbv:claim abbv:claims abbv:segment 0001551152 2024-01-01 2024-09-30 0001551152 exch:XCHI us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001551152 exch:XNYS us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2024-01-01 2024-09-30 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2024-01-01 2024-09-30 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2024-01-01 2024-09-30 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-01-01 2024-09-30 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2024-01-01 2024-09-30 0001551152 2024-10-28 0001551152 2024-07-01 2024-09-30 0001551152 2023-07-01 2023-09-30 0001551152 2023-01-01 2023-09-30 0001551152 2024-09-30 0001551152 2023-12-31 0001551152 us-gaap:CommonStockMember 2023-06-30 0001551152 us-gaap:TreasuryStockCommonMember 2023-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001551152 us-gaap:RetainedEarningsMember 2023-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001551152 us-gaap:NoncontrollingInterestMember 2023-06-30 0001551152 2023-06-30 0001551152 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001551152 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001551152 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001551152 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30